Loading...
One proposed strategy for reducing the risk for diabetes in individuals with glucose intolerance is preprandial use of nateglinide, a short-acting insulin secretagogue. In addition, some studies have suggested that renin–angiotensin inhibitors (such as angiotensin-converting–enzyme inhibitors and the angiotensin-receptor blocker valsartan) might decrease the risk for diabetes as well as risks for cardiovascular events (e.g., JW Cardiol Nov 30 2001); however, this conclusion is based on secondary endpoints, and the results have been inconsistent. To find out more, investigators conducted the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial, an industry-sponsored, placebo-controlled, randomized trial…